# Genetic Risk-Based Atrial Fibrillation Screening (GeneAF Study)

> **NCT04932798** · — · UNKNOWN · sponsor: **Montreal Heart Institute** · enrollment: 726 (estimated)

## Conditions studied

- Genetic Predisposition
- Atrial Fibrillation

## Interventions

- **DIAGNOSTIC_TEST:** Resting ECG (if first visit is done on site only)
- **DIAGNOSTIC_TEST:** 24-hour ambulatory electrocardiographic monitoring (Holter) (if first visit done on site only)
- **DIAGNOSTIC_TEST:** 3-month AF detection monitoring using the Apple Watch

## Key facts

- **NCT ID:** NCT04932798
- **Lead sponsor:** Montreal Heart Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-01
- **Primary completion:** 2026-01-10
- **Final completion:** 2026-01-10
- **Target enrollment:** 726 (ESTIMATED)
- **Last updated:** 2022-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04932798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04932798, "Genetic Risk-Based Atrial Fibrillation Screening (GeneAF Study)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04932798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*